Tianjin Ringpu Bio-Technology Co.,Ltd. agreed to acquire 20% stake in Beijing Challenge Bio-Technology Co., Ltd. from Hangzhou Zhongyu Zhichen Investment Management Partnership for CNY 48 million.
November 02, 2021
Share
Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) agreed to acquire 20% stake in Beijing Challenge Bio-Technology Co., Ltd. from Hangzhou Zhongyu Zhichen Investment Management Partnership for CNY 48 million on October 18, 2021. Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) will finance the transaction with its own funds. The deal is subject to Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) board approval. As of october 18, 2021 Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) board approved the deal.
Tianjin Ringpu Bio-Technology Co Ltd is a China-based company serving the animal health industry. The Company's main business areas are the research and development, production and sales of veterinary biological products, veterinary pharmaceutical preparations (chemicals, traditional Chinese veterinary medicines, disinfectants, and others), veterinary raw materials, veterinary functional additives, and provision of overall prevention and control of animal diseases. The Company's products include pharmaceuticals, vaccines, disinfectants, cleaning agents, and functional additives for pigs, chickens, waterfowl, cattle, sheep and pets, and others.
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. 
